Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758896 | 0.93 | FFAR4 (0.32) | CYP2E1FFAR4 | |
| SCHEMBL10242581 | 0.89 | OPRM1 (0.34) | MAPTFFAR4 | |
| SCHEMBL2624405 | 0.86 | CYP2E1 (0.40) | CYP2E1NR1I2 | |
| SCHEMBL2619611 | 0.85 | CYP2E1 (0.41) | CYP2E1HTTNR1I2 | |
| SCHEMBL2620492 | 0.84 | CYP2E1 (0.40) | CYP2E1NR1I2 | |
| SCHEMBL10247002 | 0.83 | CYP2E1 (0.38) | CYP2E1NR1I2 | |
| SCHEMBL10246789 | 0.83 | CYP2E1 (0.34) | CYP2E1HTTNR1I2 | |
| SCHEMBL2620436 | 0.82 | CYP2E1 (0.35) | CYP2E1NR1I2 | |
| SCHEMBL173159 | 0.81 | CYP2E1 (0.40) | CYP2E1HTTNR1I2 | |
| SCHEMBL2620434 | 0.79 | CYP2E1 (0.42) | CYP2E1HTTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164103-A1 | Compounds and Methods for the Treatment or Prevention of Flavivirus Infections | ZC3HAV1, YBX1, HAX1 | CYP2E1 47/4885HTT 2328/4885NR1I2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.